H LUNDBECK A/S-A SHS has explored a potential acquisition of XERIS BIOPHARMA HOLDINGS INC following discussions led by external advisers. The approach highlights strategic consolidation trends across the pharmaceutical sector. Any completed transaction would require a substantial premium over Xeris's current trading price of ~$10 per share.

Portfolio Overlap and Market Position